QIDP status is granted to drugs which act against pathogens which have a high degree of unmet need in their treatment and are identified by the Centers for Disease Control. QIDP status allows for fast track review of the drug application by U.S. FDA, paving way for an early launch. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status.
Dr. Habil Khorakiwala, Wockhardt Founder & Chairman said, "Globally there is a significant antibiotic vacuum due to dual impact of rise in new resistant pathogens and declining research in this area which causes over 50,000 deaths in USA and Europe combined despite having excellent healthcare services.
"The emerging world may as well be sitting on an antibiotic time-bomb ready to explode. Superficially the bacterial diseases can be divided in two categories, gram positive and gram negative and these pathogens have prevalence in both of them. Over the years Wockhardt has developed a strong anti-infective program which focuses on development of drugs which target this antibiotic gap in both gram positive and gram negative domains. These two drugs act against one of the globally rising class of pathogens MRSA (Methicillin-resistant Staphylococcus Aureus) which causes a range of diseases from the skin infection to severe respiratory infections.
"In case of severe infections like Hospital Acquired Pneumonia (HAP) current medical cure has a very limited reach causing a high unmet need and mortality. Both of these drugs are effective against MRSA and have shown potential in treatment of HAP. WCK 771 is an intravenous (IV) drug while WCK 2349 is a solid oral tablet, which is a significant positive for the drug development scenario as currently there is very little advance drug research in developing solid oral dosages. Most of the research is in developing intravenous drugs which requires significantly higher medical attention and increased rate of hospitalization wherein the chances of catching other infections is very high.
"In addition to the fast track review of its drug application, QIDP status also grants a 5 year extension to the drug patents in USA which is a major support for the commercial aspect of the drug. These drugs will be entering in their global Phase -3 clinical trials early next year."
Wockhardt started its Anti-infective program 17 years back in 1997 to focus on developing next generation antibiotics.
- Will New Antibiotics Reduce The Resistance Problem?
- FDA’s Pathway For Hospital Acquired Pneumonia- It's Feasible But Stupid
- Novexel Reports Positive Phase II Trial Results With NXL103 In Adult Patients With Community Acquired Pneumonia
- Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
- Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial In Hospital Patients With Complicated Urinary Tract Infections